Exact Mass: 367.1914

Exact Mass Matches: 367.1914

Found 70 metabolites which its exact mass value is equals to given mass value 367.1914, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

6-hydroxytryprostatin B

6-Hydroxytryprostatin B; Desmethyltryprostatin A

C21H25N3O3 (367.1896)


A cyclic dipeptide that is brevianamide F (cyclo-L-Trp-L-Pro) substituted at positions 2 and 6 on the indole ring by prenyl and hydroxy groups respectively.

   

Dodeca-6,8,10-trienedioylcarnitine

3-[(11-carboxyundeca-6,8,10-trienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C19H29NO6 (367.1995)


Dodeca-6,8,10-trienedioylcarnitine is an acylcarnitine. More specifically, it is an dodeca-6,8,10-trienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Dodeca-6,8,10-trienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Dodeca-6,8,10-trienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Dodeca-4,7,10-trienedioylcarnitine

3-[(11-carboxyundeca-4,7,10-trienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C19H29NO6 (367.1995)


Dodeca-4,7,10-trienedioylcarnitine is an acylcarnitine. More specifically, it is an dodeca-4,7,10-trienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Dodeca-4,7,10-trienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Dodeca-4,7,10-trienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(2E,6E,8E)-Dodeca-2,6,8-trienedioylcarnitine

3-[(11-carboxyundeca-2,6,8-trienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C19H29NO6 (367.1995)


(2E,6E,8E)-Dodeca-2,6,8-trienedioylcarnitine is an acylcarnitine. More specifically, it is an (2E,6E,8E)-dodeca-2,6,8-trienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2E,6E,8E)-Dodeca-2,6,8-trienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (2E,6E,8E)-Dodeca-2,6,8-trienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Dodeca-5,7,9-trienedioylcarnitine

3-[(11-carboxyundeca-5,7,9-trienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C19H29NO6 (367.1995)


Dodeca-5,7,9-trienedioylcarnitine is an acylcarnitine. More specifically, it is an dodeca-5,7,9-trienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Dodeca-5,7,9-trienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Dodeca-5,7,9-trienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Dodeca-4,6,8-trienedioylcarnitine

3-[(11-carboxyundeca-4,6,8-trienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C19H29NO6 (367.1995)


Dodeca-4,6,8-trienedioylcarnitine is an acylcarnitine. More specifically, it is an dodeca-4,6,8-trienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Dodeca-4,6,8-trienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Dodeca-4,6,8-trienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Dodeca-3,6,9-trienedioylcarnitine

3-[(11-carboxyundeca-3,6,9-trienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C19H29NO6 (367.1995)


Dodeca-3,6,9-trienedioylcarnitine is an acylcarnitine. More specifically, it is an dodeca-3,6,9-trienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Dodeca-3,6,9-trienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Dodeca-3,6,9-trienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3,4-Dehydrocilostazol

6-[4-(1-cyclohexyl-1H-1,2,3,4-tetrazol-5-yl)butoxy]-1,2-dihydroquinolin-2-one

C20H25N5O2 (367.2008)


   

{4-[4-(6-Carbamoyl-3,5-dimethylpyrazin-2-yl)phenyl]cyclohexyl}acetic acid

2-{4-[4-(6-carbamoyl-3,5-dimethylpyrazin-2-yl)phenyl]cyclohexyl}acetic acid

C21H25N3O3 (367.1896)


AZD7687 is a potent, selective, reversible and orally active diacylglycerol acyltransferase 1 (DGAT1) inhibitor with an IC50 of 80 nM for human DGAT1. AZD7687 can be used for type 2 diabetes mellitus and obesity research[1][2].

   
   
   
   

Desmethyltryprostatin A

Desmethyltryprostatin A

C21H25N3O3 (367.1896)


   

6-Hydroxydeoxybrevianamide E

6-Hydroxydeoxybrevianamide E

C21H25N3O3 (367.1896)


   
   

Oprea1_213167

Oprea1_213167

C23H29NOS (367.197)


   

12-hydroxy-4,19-dimethyl-(13betaH,14betaH)-14,19-dihydro-4,8-seco-crotalanane-8,11,15-trione|8,12-dihydroxy-4alpha,19-dimethyl-11,15-dioxo-(13betaH,14betaH)-14,19-dihydro-crotalananium betaine|Crosemperin|crosemperine

12-hydroxy-4,19-dimethyl-(13betaH,14betaH)-14,19-dihydro-4,8-seco-crotalanane-8,11,15-trione|8,12-dihydroxy-4alpha,19-dimethyl-11,15-dioxo-(13betaH,14betaH)-14,19-dihydro-crotalananium betaine|Crosemperin|crosemperine

C19H29NO6 (367.1995)


   
   

4-[3-[N-[[(2S,3S)-3-trans-carboxyoxiran-2-yl]carbonyl]-L-leucyl]aminopropanyl]-1H-imidazol-2-ylamine|WF14865B

4-[3-[N-[[(2S,3S)-3-trans-carboxyoxiran-2-yl]carbonyl]-L-leucyl]aminopropanyl]-1H-imidazol-2-ylamine|WF14865B

C16H25N5O5 (367.1856)


   

SIRT1 Activator 3

SIRT1 Activator 3

C20H25N5O2 (367.2008)


   

N-Desethylquinagolide

N-Desethylquinagolide

C18H29N3O3S (367.193)


   

CAY10591

2-amino-N-cyclopentyl-1-(3-methoxypropyl)-1H-pyrrolo[2,3-b]quinoxaline-3-carboxamide

C20H25N5O2 (367.2008)


   
   

3,4-Dehydrocilostazol

3,4-Dehydro Cilostazol

C20H25N5O2 (367.2008)


   

3-METHYL-4-(4-(PYRIDIN-2-YLMETHOXY)CYCLOHEXANECARBOXAMIDO)BENZAMIDE

3-METHYL-4-(4-(PYRIDIN-2-YLMETHOXY)CYCLOHEXANECARBOXAMIDO)BENZAMIDE

C21H25N3O3 (367.1896)


   

4-METHYL-3-(4-(PYRIDIN-2-YLMETHOXY)CYCLOHEXANECARBOXAMIDO)BENZAMIDE

4-METHYL-3-(4-(PYRIDIN-2-YLMETHOXY)CYCLOHEXANECARBOXAMIDO)BENZAMIDE

C21H25N3O3 (367.1896)


   

butyl prop-2-enoate,methyl 2-methylprop-2-enoate,2-methylprop-2-enoic acid,prop-2-enenitrile

butyl prop-2-enoate,methyl 2-methylprop-2-enoate,2-methylprop-2-enoic acid,prop-2-enenitrile

C19H29NO6 (367.1995)


   

1,4-divinylbenzene,isocyanatomethylbenzene,styrene

1,4-divinylbenzene,isocyanatomethylbenzene,styrene

C26H25NO (367.1936)


   

Tiracizine

CARBAMIC ACID

C21H25N3O3 (367.1896)


C78274 - Agent Affecting Cardiovascular System > C47793 - Antiarrhythmic Agent D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents C - Cardiovascular system > C01 - Cardiac therapy

   

ETHYL 2-AMINO-5-((7-ETHOXY-7-OXOHEPTYL)OXY)-4-METHOXYBENZOATE

ETHYL 2-AMINO-5-((7-ETHOXY-7-OXOHEPTYL)OXY)-4-METHOXYBENZOATE

C19H29NO6 (367.1995)


   

2,6-Difluoro-3,5-bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine

2,6-Difluoro-3,5-bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine

C17H25B2F2NO4 (367.1938)


   

2-amino-N-cyclopentyl-1-(3-methoxypropyl)-1H-pyrrolo[2,3-b]quinoxaline-3-carboxamide

2-amino-N-cyclopentyl-1-(3-methoxypropyl)-1H-pyrrolo[2,3-b]quinoxaline-3-carboxamide

C20H25N5O2 (367.2008)


D020536 - Enzyme Activators

   

2-N-acetylparomamine(2+)

2-N-acetylparomamine(2+)

C14H29N3O8+2 (367.1955)


   

Dodeca-5,7,9-trienedioylcarnitine

Dodeca-5,7,9-trienedioylcarnitine

C19H29NO6 (367.1995)


   

Dodeca-4,6,8-trienedioylcarnitine

Dodeca-4,6,8-trienedioylcarnitine

C19H29NO6 (367.1995)


   

Dodeca-3,6,9-trienedioylcarnitine

Dodeca-3,6,9-trienedioylcarnitine

C19H29NO6 (367.1995)


   

Dodeca-6,8,10-trienedioylcarnitine

Dodeca-6,8,10-trienedioylcarnitine

C19H29NO6 (367.1995)


   

Dodeca-4,7,10-trienedioylcarnitine

Dodeca-4,7,10-trienedioylcarnitine

C19H29NO6 (367.1995)


   

(2E,6E,8E)-Dodeca-2,6,8-trienedioylcarnitine

(2E,6E,8E)-Dodeca-2,6,8-trienedioylcarnitine

C19H29NO6 (367.1995)


   

Ipratropium chloride

Ipratropium chloride

C20H30ClNO3 (367.1914)


   

2-[4-[(2R)-2-[(3S,5S)-3,5-dimethyl-2-oxocyclohexyl]-2-hydroxyethyl]-2,6-dioxo-1-piperidinyl]acetic acid ethyl ester

2-[4-[(2R)-2-[(3S,5S)-3,5-dimethyl-2-oxocyclohexyl]-2-hydroxyethyl]-2,6-dioxo-1-piperidinyl]acetic acid ethyl ester

C19H29NO6 (367.1995)


   

N-[2-(4-acetyl-1-piperazinyl)phenyl]-2-(2-methylphenoxy)acetamide

N-[2-(4-acetyl-1-piperazinyl)phenyl]-2-(2-methylphenoxy)acetamide

C21H25N3O3 (367.1896)


   

2-[(6-methoxy-4-methylquinazolin-2-yl)amino]-6-methyl-5-(3-methylbutyl)pyrimidin-4(3H)-one

2-[(6-methoxy-4-methylquinazolin-2-yl)amino]-6-methyl-5-(3-methylbutyl)pyrimidin-4(3H)-one

C20H25N5O2 (367.2008)


   

(2S,3S)-3-{[(2S)-1-{[3-(2-amino-1H-imidazol-4-yl)propyl]amino}-4-methyl-1-oxopentan-2-yl]carbamoyl}oxirane-2-carboxylic acid

(2S,3S)-3-{[(2S)-1-{[3-(2-amino-1H-imidazol-4-yl)propyl]amino}-4-methyl-1-oxopentan-2-yl]carbamoyl}oxirane-2-carboxylic acid

C16H25N5O5 (367.1856)


   

(3R,3aS,7R,7aS)-7-methyl-3-(2-naphthalenyl)-2-(phenylmethyl)-3a,6,7,7a-tetrahydro-3H-isoindol-1-one

(3R,3aS,7R,7aS)-7-methyl-3-(2-naphthalenyl)-2-(phenylmethyl)-3a,6,7,7a-tetrahydro-3H-isoindol-1-one

C26H25NO (367.1936)


   

N-hydroxy-N-[(E)-(4-phenylphenyl)methylideneamino]octanediamide

N-hydroxy-N-[(E)-(4-phenylphenyl)methylideneamino]octanediamide

C21H25N3O3 (367.1896)


   

N-hydroxy-N-[(E)-[4-(2-methylphenyl)phenyl]methylideneamino]heptanediamide

N-hydroxy-N-[(E)-[4-(2-methylphenyl)phenyl]methylideneamino]heptanediamide

C21H25N3O3 (367.1896)


   

(2S,3S)-3-{[(2R)-1-{[3-(2-amino-1H-imidazol-4-yl)propyl]amino}-3-methyl-1-oxopentan-2-yl]carbamoyl}oxirane-2-carboxylic acid

(2S,3S)-3-{[(2R)-1-{[3-(2-amino-1H-imidazol-4-yl)propyl]amino}-3-methyl-1-oxopentan-2-yl]carbamoyl}oxirane-2-carboxylic acid

C16H25N5O5 (367.1856)


   

N-[4-[(3-phenylpropanoylamino)carbamoyl]phenyl]pentanamide

N-[4-[(3-phenylpropanoylamino)carbamoyl]phenyl]pentanamide

C21H25N3O3 (367.1896)


   

3-ethoxy-N-[(4-methoxyphenyl)methyl]-2-propyl-6-indazolecarboxamide

3-ethoxy-N-[(4-methoxyphenyl)methyl]-2-propyl-6-indazolecarboxamide

C21H25N3O3 (367.1896)


   

2-[[(E)-2-acetamido-3-hydroxyoct-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(E)-2-acetamido-3-hydroxyoct-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C15H32N2O6P+ (367.1998)


   

WF14865B

WF14865B

C16H25N5O5 (367.1856)


A member of the class of guanidines isolated from the culture mycelium of the fungal strain Aphanoascus fulvescens and has been shown to exhibit inhibitory activity against cathepsin B and L.

   

WF14865A

WF14865A

C16H25N5O5 (367.1856)


A member of the class of guanidines isolated from the culture mycelium of the fungal strain Aphanoascus fulvescens and has been shown to exhibit inhibitory activity against cathepsin B and L.

   
   

3-[(1-{[3-(2-imino-1,3-dihydroimidazol-4-yl)propyl]-c-hydroxycarbonimidoyl}-3-methylbutyl)-c-hydroxycarbonimidoyl]oxirane-2-carboxylic acid

3-[(1-{[3-(2-imino-1,3-dihydroimidazol-4-yl)propyl]-c-hydroxycarbonimidoyl}-3-methylbutyl)-c-hydroxycarbonimidoyl]oxirane-2-carboxylic acid

C16H25N5O5 (367.1856)


   

(2s,3s)-3-{[(1s,2s)-1-{[3-(2-imino-1,3-dihydroimidazol-4-yl)propyl]-c-hydroxycarbonimidoyl}-2-methylbutyl]-c-hydroxycarbonimidoyl}oxirane-2-carboxylic acid

(2s,3s)-3-{[(1s,2s)-1-{[3-(2-imino-1,3-dihydroimidazol-4-yl)propyl]-c-hydroxycarbonimidoyl}-2-methylbutyl]-c-hydroxycarbonimidoyl}oxirane-2-carboxylic acid

C16H25N5O5 (367.1856)


   

(1s,4s,10s,12r)-12-hydroxy-1-(2-methylbut-3-en-2-yl)-2,8,19-triazapentacyclo[10.7.0.0²,¹⁰.0⁴,⁸.0¹³,¹⁸]nonadeca-13,15,17-triene-3,9-dione

(1s,4s,10s,12r)-12-hydroxy-1-(2-methylbut-3-en-2-yl)-2,8,19-triazapentacyclo[10.7.0.0²,¹⁰.0⁴,⁸.0¹³,¹⁸]nonadeca-13,15,17-triene-3,9-dione

C21H25N3O3 (367.1896)


   

alistonitrine A

NA

C21H25N3O3 (367.1896)


{"Ingredient_id": "HBIN015160","Ingredient_name": "alistonitrine A","Alias": "NA","Ingredient_formula": "C21H25N3O3","Ingredient_Smile": "CC1C2(O1)C3CC4C56C(C3C(=O)OC)(CCN5C2N4C)C7=CC=CC=C7N6","Ingredient_weight": "367.4 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "35060","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "102222299","DrugBank_id": "NA"}

   

(2s,3s)-3-{[(1s)-1-{[3-(2-imino-1,3-dihydroimidazol-4-yl)propyl]-c-hydroxycarbonimidoyl}-3-methylbutyl]-c-hydroxycarbonimidoyl}oxirane-2-carboxylic acid

(2s,3s)-3-{[(1s)-1-{[3-(2-imino-1,3-dihydroimidazol-4-yl)propyl]-c-hydroxycarbonimidoyl}-3-methylbutyl]-c-hydroxycarbonimidoyl}oxirane-2-carboxylic acid

C16H25N5O5 (367.1856)


   

(2e)-n-[(1s,2s,4s,5s,6s,7r,8s)-1,5,7-trihydroxy-10-oxo-3-oxatricyclo[4.3.1.0²,⁴]decan-8-yl]dec-2-enimidic acid

(2e)-n-[(1s,2s,4s,5s,6s,7r,8s)-1,5,7-trihydroxy-10-oxo-3-oxatricyclo[4.3.1.0²,⁴]decan-8-yl]dec-2-enimidic acid

C19H29NO6 (367.1995)


   

5-({2-imino-5-[(4-methoxyphenyl)methyl]-1,3-dimethylimidazol-4-yl}methyl)-2-methoxyphenol

5-({2-imino-5-[(4-methoxyphenyl)methyl]-1,3-dimethylimidazol-4-yl}methyl)-2-methoxyphenol

C21H25N3O3 (367.1896)


   

(3s,8as)-1-hydroxy-3-{[6-hydroxy-2-(3-methylbut-2-en-1-yl)-1h-indol-3-yl]methyl}-3h,6h,7h,8h,8ah-pyrrolo[1,2-a]pyrazin-4-one

(3s,8as)-1-hydroxy-3-{[6-hydroxy-2-(3-methylbut-2-en-1-yl)-1h-indol-3-yl]methyl}-3h,6h,7h,8h,8ah-pyrrolo[1,2-a]pyrazin-4-one

C21H25N3O3 (367.1896)


   

6-hydroxy-4-isopropyl-5,6,13-trimethyl-2,8-dioxa-13-azabicyclo[8.5.1]hexadec-10-ene-3,7,16-trione

6-hydroxy-4-isopropyl-5,6,13-trimethyl-2,8-dioxa-13-azabicyclo[8.5.1]hexadec-10-ene-3,7,16-trione

C19H29NO6 (367.1995)


   

1-hydroxy-3-{[6-hydroxy-2-(3-methylbut-2-en-1-yl)-1h-indol-3-yl]methyl}-3h,6h,7h,8h,8ah-pyrrolo[1,2-a]pyrazin-4-one

1-hydroxy-3-{[6-hydroxy-2-(3-methylbut-2-en-1-yl)-1h-indol-3-yl]methyl}-3h,6h,7h,8h,8ah-pyrrolo[1,2-a]pyrazin-4-one

C21H25N3O3 (367.1896)


   

3-[(1-{[3-(2-imino-1,3-dihydroimidazol-4-yl)propyl]-c-hydroxycarbonimidoyl}-2-methylbutyl)-c-hydroxycarbonimidoyl]oxirane-2-carboxylic acid

3-[(1-{[3-(2-imino-1,3-dihydroimidazol-4-yl)propyl]-c-hydroxycarbonimidoyl}-2-methylbutyl)-c-hydroxycarbonimidoyl]oxirane-2-carboxylic acid

C16H25N5O5 (367.1856)


   

(2e)-n-[(1s,2s,4s,5r,6s,7s,8s)-1,5,7-trihydroxy-10-oxo-3-oxatricyclo[4.3.1.0²,⁴]decan-8-yl]dec-2-enimidic acid

(2e)-n-[(1s,2s,4s,5r,6s,7s,8s)-1,5,7-trihydroxy-10-oxo-3-oxatricyclo[4.3.1.0²,⁴]decan-8-yl]dec-2-enimidic acid

C19H29NO6 (367.1995)


   

n-{1,5,7-trihydroxy-10-oxo-3-oxatricyclo[4.3.1.0²,⁴]decan-8-yl}dec-2-enimidic acid

n-{1,5,7-trihydroxy-10-oxo-3-oxatricyclo[4.3.1.0²,⁴]decan-8-yl}dec-2-enimidic acid

C19H29NO6 (367.1995)


   

(1r,4r,5s,6r,10z)-6-hydroxy-4-isopropyl-5,6,13-trimethyl-2,8-dioxa-13-azabicyclo[8.5.1]hexadec-10-ene-3,7,16-trione

(1r,4r,5s,6r,10z)-6-hydroxy-4-isopropyl-5,6,13-trimethyl-2,8-dioxa-13-azabicyclo[8.5.1]hexadec-10-ene-3,7,16-trione

C19H29NO6 (367.1995)


   

n-[(1s,2s,4s,5r,6s,7s,8s)-1,5,7-trihydroxy-10-oxo-3-oxatricyclo[4.3.1.0²,⁴]decan-8-yl]dec-2-enimidic acid

n-[(1s,2s,4s,5r,6s,7s,8s)-1,5,7-trihydroxy-10-oxo-3-oxatricyclo[4.3.1.0²,⁴]decan-8-yl]dec-2-enimidic acid

C19H29NO6 (367.1995)


   

12-hydroxy-1-(2-methylbut-3-en-2-yl)-2,8,19-triazapentacyclo[10.7.0.0²,¹⁰.0⁴,⁸.0¹³,¹⁸]nonadeca-13,15,17-triene-3,9-dione

12-hydroxy-1-(2-methylbut-3-en-2-yl)-2,8,19-triazapentacyclo[10.7.0.0²,¹⁰.0⁴,⁸.0¹³,¹⁸]nonadeca-13,15,17-triene-3,9-dione

C21H25N3O3 (367.1896)